GLIMDA MV 2MG TABLET is a combination of Glimepiride, Metformin and Voglibose, which belongs to the group of medicines called Antidiabetic agents. GLIMDA MV 2MG TABLET is used in adults to manage type 2 diabetes mellitus when diet, exercise, and single-agent or second-line therapy with two drugs are insufficient to adequately control blood sugar levels.

GLIMDA MV 2MG TABLET is not recommended for use in patients allergic to glimepiride, metformin, voglibose, and/or other sulfonylureas or sulphonamides. It is also not recommended for use in patients with acute conditions (such as dehydration or severe infection), severe ketosis (a severe complication of diabetes), severe trauma, lung problems (such as acute or chronic respiratory failure), heart problems (such as acute or chronic cardiac failure or recent myocardial infarction), and/or severe kidney or liver problems.

Before taking GLIMDA MV 2MG TABLET, inform your doctor if you recently had trauma and/or have febrile infections, fever, uncontrolled diabetes, hypothyroidism (underactive thyroid), chronic intestinal disease, fever, or other kidney or liver problems.

GLIMDA MV 2MG TABLET is not recommended for use in pregnant and breastfeeding women since it may cause harm to the developing foetus or nursing child.

GLIMDA MV 2MG TABLET is also not recommended for use in children and adolescents (aged below 18 years) and is advised to be used with caution in elderly patients (aged 75 years or older) after consulting the doctor.

The most common side effects of GLIMDA MV 2MG TABLET are nausea and vomiting, diarrhea, abdominal pain, loss of appetite, metallic taste, and/or hypoglycemia (low blood sugar). Consult your doctor if any of these side effects worsen.